10:58,
YEREVAN, MAY 26, ARMENPRESS. Neuralink, the neurotech startup co-founded by business magnate and investor Elon Musk, announced Thursday it has received approval from the U.S. Food and Drug Administration (FDA) to conduct its first in-human clinical study.
Neuralink is building a brain implant called the Link, which aims to help patients with severe paralysis control external technologies using only neural signals. This means patients with severe degenerative diseases like ALS could eventually regain their ability to communicate with loved ones by moving cursors and typing with their minds, CNBC reported.
“This is the result of incredible work by the Neuralink team in close collaboration with the FDA and represents an important first step that will one day allow our technology to help many people,” the company tweeted.